Metformin- A Promising Agent for Chemoprevention in Carriers.
作者信息
Kumar Nagi B, Vadaparampil Susan T, Mahajan Nupam, Lilienfeld Howard S, Lee Ji-Hyun, Laronga Christine, Hakam Ardeshir, Hein John J, Egan Kathleen M, Arun Banu, Pal Tuya
机构信息
Departments of Cancer Epidemiology The University of Texas MD Anderson Cancer Center, Houston, Texas ; Oncological Sciences University of South Florida College of Medicine, Tampa Florida.
Health Outcomes and Behavior, The University of Texas MD Anderson Cancer Center, Houston, Texas ; Oncological Sciences University of South Florida College of Medicine, Tampa Florida.
出版信息
Hereditary Genet. 2012 Jun;1(2). doi: 10.4172/2161-1041.1000104.
Abstract
摘要
相似文献
1
Metformin- A Promising Agent for Chemoprevention in Carriers.
Hereditary Genet. 2012 Jun;1(2). doi: 10.4172/2161-1041.1000104.
2
Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based "starvation" strategies in BRCA1 carriers.
Oncotarget. 2016 Aug 16;7(33):52974-52992. doi: 10.18632/oncotarget.9732.
3
BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials.
J Cell Biochem Suppl. 2000;34:13-8.
4
Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
J Clin Oncol. 2000 Nov 1;18(21 Suppl):93S-9S.
5
Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics.
Fam Cancer. 2008;7(1):83-9. doi: 10.1007/s10689-007-9147-7. Epub 2007 Jul 12.
6
Hereditary breast cancer. Identifying and managing BRCA1 and BRCA2 carriers.
Can Fam Physician. 1999 Jan;45:114-24.
7
Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
Clin Genet. 2006 Sep;70(3):198-206. doi: 10.1111/j.1399-0004.2006.00665.x.
8
Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers.
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):654-8. doi: 10.1158/1078-0432.CCR-06-1902.
9
Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment.
BMJ Open. 2018 Dec 22;8(12):e023115. doi: 10.1136/bmjopen-2018-023115.
10
Excretion of estrogens, catecholestrogens and phytoestrogens in carriers of BRCA1 gene mutations: effects of metformin.
Neoplasma. 2010;57(4):333-8. doi: 10.4149/neo_2010_04_333.
引用本文的文献
1
Metformin and Chemoprevention: Potential for Heart-Healthy Targeting of Biologically Aggressive Breast Cancer.
Front Public Health. 2020 Oct 29;8:509714. doi: 10.3389/fpubh.2020.509714. eCollection 2020.
2
On metabolic reprogramming and tumor biology: A comprehensive survey of metabolism in breast cancer.
Oncotarget. 2016 Oct 11;7(41):67626-67649. doi: 10.18632/oncotarget.11759.
本文引用的文献
1
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Mol Cancer Ther. 2010 May;9(5):1092-9. doi: 10.1158/1535-7163.MCT-09-1186. Epub 2010 May 4.
2
Excretion of estrogens, catecholestrogens and phytoestrogens in carriers of BRCA1 gene mutations: effects of metformin.
Neoplasma. 2010;57(4):333-8. doi: 10.4149/neo_2010_04_333.
3
Long-term metformin use is associated with decreased risk of breast cancer.
Diabetes Care. 2010 Jun;33(6):1304-8. doi: 10.2337/dc09-1791. Epub 2010 Mar 18.
4
Expanding the arsenal: metformin for the treatment of triple-negative breast cancer?
Cell Cycle. 2009 Sep 1;8(17):2681. doi: 10.4161/cc.8.17.9502.
5
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes.
Diabetes Care. 2009 Sep;32(9):1620-5. doi: 10.2337/dc08-2175. Epub 2009 Jun 29.
6
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.
J Clin Oncol. 2009 Jul 10;27(20):3297-302. doi: 10.1200/JCO.2009.19.6410. Epub 2009 Jun 1.
7
Antidiabetic medication and prostate cancer risk: a population-based case-control study.
Am J Epidemiol. 2008 Oct 15;168(8):925-31. doi: 10.1093/aje/kwn190. Epub 2008 Aug 11.
8
The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.
Oncogene. 2008 Jun 5;27(25):3576-86. doi: 10.1038/sj.onc.1211024. Epub 2008 Jan 21.
9
International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
Int J Cancer. 2008 May 1;122(9):2017-22. doi: 10.1002/ijc.23340.
10
Variation of breast cancer risk among BRCA1/2 carriers.
JAMA. 2008 Jan 9;299(2):194-201. doi: 10.1001/jama.2007.55-a.
Zotero 插件